176 related articles for article (PubMed ID: 23564916)
1. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).
Lonn EM; Bosch J; Diaz R; Lopez-Jaramillo P; Ramachandran A; Hâncu N; Hanefeld M; Krum H; Ryden L; Smith S; McQueen MJ; Dyal L; Yusuf S; Gerstein HC;
Diabetes Care; 2013 Sep; 36(9):2466-74. PubMed ID: 23564916
[TBL] [Abstract][Full Text] [Related]
2. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
3. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
4. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale JF; Yusuf S; Gerstein HC;
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):562-72. PubMed ID: 24898834
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
; Gerstein H; Yusuf S; Riddle MC; Ryden L; Bosch J
Am Heart J; 2008 Jan; 155(1):26-32, 32.e1-6. PubMed ID: 18082485
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
[TBL] [Abstract][Full Text] [Related]
7. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
; Bosch J; Gerstein HC; Dagenais GR; Díaz R; Dyal L; Jung H; Maggiono AP; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):309-18. PubMed ID: 22686415
[TBL] [Abstract][Full Text] [Related]
8. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia.
Bordeleau L; Yakubovich N; Dagenais GR; Rosenstock J; Probstfield J; Chang Yu P; Ryden LE; Pirags V; Spinas GA; Birkeland KI; Ratner RE; Marin-Neto JA; Keltai M; Riddle MC; Bosch J; Yusuf S; Gerstein HC;
Diabetes Care; 2014; 37(5):1360-6. PubMed ID: 24574355
[TBL] [Abstract][Full Text] [Related]
9. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.
ORIGIN Trial Investigators
Diabetes Care; 2013 Oct; 36(10):2915-22. PubMed ID: 23656980
[TBL] [Abstract][Full Text] [Related]
10. Effects of magnesium supplementation on carotid intima-media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial.
Talari HR; Zakizade M; Soleimani A; Bahmani F; Ghaderi A; Mirhosseini N; Eslahi M; Babadi M; Mansournia MA; Asemi Z
Br J Nutr; 2019 Apr; 121(7):809-817. PubMed ID: 30739626
[TBL] [Abstract][Full Text] [Related]
11. Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Petrie JR; Chaturvedi N; Ford I; Hramiak I; Hughes AD; Jenkins AJ; E Klein B; Klein R; Ooi TC; Rossing P; Sattar N; Stehouwer CD; Colhoun HM;
Diabetes Obes Metab; 2017 Apr; 19(4):509-516. PubMed ID: 27935183
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
Zhang J; Xian TZ; Wu MX; Li C; Pan Q; Guo LX
Cardiovasc Diabetol; 2020 Apr; 19(1):48. PubMed ID: 32334592
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of carotid intima media thickness in impaired fasting glucose and impaired glucose tolerance.
Aydin Y; Berker D; Ustün I; Gül K; Erden G; Kutlucan A; Yilmaz Aydin L; Güler S
Minerva Endocrinol; 2011 Sep; 36(3):171-9. PubMed ID: 22019748
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Zheng H; Li H; Wang Y; Li Z; Hu B; Li X; Fu L; Hu H; Nie Z; Zhao B; Wei D; Karlson BW; Bots ML; Meng X; Chen Y; Wang Y;
Stroke; 2022 Oct; 53(10):3004-3013. PubMed ID: 36017704
[TBL] [Abstract][Full Text] [Related]
15. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Preiss D; Lloyd SM; Ford I; McMurray JJ; Holman RR; Welsh P; Fisher M; Packard CJ; Sattar N
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):116-24. PubMed ID: 24622715
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial.
O'Mahoney LL; Dunseath G; Churm R; Holmes M; Boesch C; Stavropoulos-Kalinoglou A; Ajjan RA; Birch KM; Orsi NM; Mappa G; Price OJ; Campbell MD
Cardiovasc Diabetol; 2020 Aug; 19(1):127. PubMed ID: 32787879
[TBL] [Abstract][Full Text] [Related]
17. The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD.
Asemi Z; Raygan F; Bahmani F; Rezavandi Z; Talari HR; Rafiee M; Poladchang S; Darooghegi Mofrad M; Taheri S; Mohammadi AA; Esmaillzadeh A
Br J Nutr; 2016 Jul; 116(2):286-93. PubMed ID: 27198036
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids supplementation improves early-stage diabetic nephropathy and subclinical atherosclerosis in pediatric patients with type 1 diabetes: A randomized controlled trial.
Elbarbary NS; Ismail EAR; Mohamed SA
Clin Nutr; 2023 Dec; 42(12):2372-2380. PubMed ID: 37862823
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).
ORIGIN Trial Investigators
Diabetes Care; 2016 May; 39(5):709-16. PubMed ID: 26681720
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
